Kim Holly H, Daar Eric S
Division of HIV Medicine and Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and the David Geffen School of Medicine at UCLA, 1124 W. Carson Street, N-24, Torrance, CA 90502, USA.
Curr HIV/AIDS Rep. 2009 May;6(2):55-62. doi: 10.1007/s11904-009-0009-9.
Several relatively new antiretroviral drugs have been approved or are under investigation. These include nucleoside and nonnucleoside reverse transcriptase inhibitors, protease and integrase strand transfer inhibitors, CCR5 antagonists, and an entirely new class of maturation inhibitors. Although most of these drugs were developed for patients with drug-resistant HIV-1, some have demonstrated a potential role for those starting treatment for the first time. This review incorporates data from the most recent treatment guidelines, peer-reviewed publications, and recent presentations at research meetings about some of these relatively new and emerging antiretroviral agents and offers strategies for incorporating them into clinical practice.
几种相对较新的抗逆转录病毒药物已获批准或正在研究中。这些药物包括核苷类和非核苷类逆转录酶抑制剂、蛋白酶和整合酶链转移抑制剂、CCR5拮抗剂，以及全新一类的成熟抑制剂。尽管这些药物大多是为耐药HIV-1患者研发的，但有些药物已显示出对初治患者的潜在作用。本综述纳入了最新治疗指南、同行评审出版物以及研究会议上有关这些相对较新和正在出现的抗逆转录病毒药物的最新数据，并提供了将它们纳入临床实践的策略。
